ID23375A - Metode pengobatan penyakit mata kering dengan agonist-agonist reseptor purinergik - Google Patents

Metode pengobatan penyakit mata kering dengan agonist-agonist reseptor purinergik

Info

Publication number
ID23375A
ID23375A IDW990977A ID990977A ID23375A ID 23375 A ID23375 A ID 23375A ID W990977 A IDW990977 A ID W990977A ID 990977 A ID990977 A ID 990977A ID 23375 A ID23375 A ID 23375A
Authority
ID
Indonesia
Prior art keywords
triphosphate
purinergic receptor
subject
agonistics
disclosed
Prior art date
Application number
IDW990977A
Other languages
English (en)
Indonesian (id)
Inventor
Benjamin R Yerxa
Karla M Jacobus
William Pendergast
Janet L Rideout
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25170925&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID23375(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Publication of ID23375A publication Critical patent/ID23375A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IDW990977A 1997-02-06 1998-02-06 Metode pengobatan penyakit mata kering dengan agonist-agonist reseptor purinergik ID23375A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/797,472 US5900407A (en) 1997-02-06 1997-02-06 Method of treating dry eye disease with uridine triphosphates and related compounds

Publications (1)

Publication Number Publication Date
ID23375A true ID23375A (id) 2000-04-20

Family

ID=25170925

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW990977A ID23375A (id) 1997-02-06 1998-02-06 Metode pengobatan penyakit mata kering dengan agonist-agonist reseptor purinergik

Country Status (20)

Country Link
US (6) US5900407A (pt)
EP (1) EP1003474B1 (pt)
JP (3) JP3652707B2 (pt)
KR (1) KR100378443B1 (pt)
CN (1) CN1151775C (pt)
AT (1) ATE428400T1 (pt)
AU (1) AU735684B2 (pt)
BR (1) BR9809562A (pt)
CA (1) CA2280183C (pt)
DE (1) DE69840746D1 (pt)
DK (1) DK1003474T3 (pt)
ES (1) ES2325892T3 (pt)
HK (1) HK1025915A1 (pt)
ID (1) ID23375A (pt)
MY (1) MY120023A (pt)
NO (1) NO329118B1 (pt)
NZ (1) NZ337405A (pt)
PT (1) PT1003474E (pt)
WO (1) WO1998034593A1 (pt)
ZA (1) ZA98979B (pt)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423694B1 (en) * 1996-02-21 2002-07-23 Inspire Pharmaceuticals, Inc. Method of treating otitis media with uridine triphosphates and related compounds
US6420347B1 (en) * 1997-03-27 2002-07-16 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
US6673779B2 (en) * 1996-03-27 2004-01-06 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with dinucleoside polyphosphate compounds or UTP analogues
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5763447C1 (en) * 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US6696425B2 (en) * 1997-02-06 2004-02-24 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
US6921755B2 (en) * 1998-02-06 2005-07-26 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
US7078391B2 (en) 1997-02-10 2006-07-18 Inspire Pharmaceuticals, Inc. Method of treating edematous retinal disorders
US6596725B2 (en) 1997-02-10 2003-07-22 Inspire Pharmaceuticals, Inc. Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
US7223744B2 (en) * 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
TW593331B (en) * 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
US6872710B2 (en) * 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
BRPI9810436B1 (pt) 1997-07-25 2015-12-29 Inspire Pharmaceuticals Inc processo para a produção em larga escala de di (5'-tetrafosfato de uridina) e sais do mesmo
US6462028B2 (en) 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
US6548658B2 (en) * 1997-07-25 2003-04-15 Inspire Pharmaceuticals, Inc. Di-(uridine 5′)-tetraphosphate and salts thereof
ATE232733T1 (de) * 1998-05-22 2003-03-15 Inspire Pharmaceuticals Inc Therapeutische dinucleotide und deren derivate
CA2355227A1 (en) * 1998-12-23 2000-07-06 Richard C. Boucher, Jr. Targeted gene transfer using g protein coupled receptors
AR023088A1 (es) * 1999-02-26 2002-09-04 Inspire Pharmaceuticals Inc Uso de disfosfatos de uridina, adenina y citidina y analogos de los mismos para la manufactura de un medicamento para la estimulacion de la hidratacion delas mucosas.
DE60021629T2 (de) * 1999-06-30 2006-01-05 Yamasa Corp., Choshi Dinukleotid-Kristalle
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6723737B1 (en) * 1999-10-20 2004-04-20 Eliezer Rapaport Methods, pharmaceutical and therapeutic compostions for administering adenosine
AU8028600A (en) * 1999-10-20 2001-04-30 Eliezer Rapaport Methods, pharmaceutical and therapeutic compositions for administering adenosine
US6277855B1 (en) 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US6864243B1 (en) 2000-05-12 2005-03-08 Inspire Pharmaceuticals, Inc. Method for treating retinal degeneration with purinergic receptor agonists
CA2413928C (en) 2000-05-30 2011-01-25 Santen Pharmaceutical Co., Ltd. Corneal epithelial migration promoter
US6555675B2 (en) 2000-08-21 2003-04-29 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7132408B2 (en) * 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US6867199B2 (en) 2000-08-21 2005-03-15 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapeutic use
US7115585B2 (en) * 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
JP3945625B2 (ja) * 2001-03-30 2007-07-18 株式会社イーエムアイ 角膜上皮障害モデル動物及びそのモデル動物を用いた薬剤の評価方法並びにその評価方法を用いて選択された薬剤
US7629329B2 (en) 2001-06-04 2009-12-08 Tsi Health Sciences, Inc. Method for increasing muscle mass and strength through administration of adenosine triphosphate
AR034635A1 (es) 2001-06-25 2004-03-03 Inspire Pharmaceuticals Inc Lubricacion de las articulaciones con agonistas del receptor purinergico p2y
CN1228053C (zh) * 2001-09-11 2005-11-23 参天制药株式会社 含有二尿苷磷酸的滴眼液
AU2002342672A1 (en) * 2001-09-11 2003-03-24 Nascacell Gmbh Method for screening for inhibitors of protein/protein interaction and corresponding ribozymes
WO2003028712A2 (en) * 2001-09-28 2003-04-10 Universite Libre De Bruxelles Purinergic and pyrimidinergic receptor agonists for the treatment of activated cd4+ t lymphocyte-mediated immune diseases
US20030109508A1 (en) * 2001-10-11 2003-06-12 Alcon, Inc. Methods for treating dry eye
KR20050030884A (ko) * 2001-10-11 2005-03-31 알콘, 인코퍼레이티드 항염증성 스테로이드 및 ｍｕｃ-1 분비촉진제 배합에 의한안구 건조증 치료 방법
WO2003030892A1 (en) * 2001-10-11 2003-04-17 Alcon, Inc. Methods for treating dry eye
US7256183B2 (en) * 2001-11-06 2007-08-14 Inspire Pharmaceuticals, Inc. Method for treating or preventing inflammatory diseases
US7084128B2 (en) * 2002-01-18 2006-08-01 Inspire Pharmaceuticals, Inc. Method for reducing intraocular pressure
US7435724B2 (en) * 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
MXPA05004121A (es) * 2002-10-18 2006-02-17 Molichem Medicines Inc Metodos para tratar la enfermedad de ojo reseco con lantibioticos.
US6984628B2 (en) * 2003-07-15 2006-01-10 Allergan, Inc. Ophthalmic compositions comprising trefoil factor family peptides
US7326683B2 (en) * 2004-05-06 2008-02-05 Molichem Medicines, Inc. Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
CA2565545A1 (en) * 2004-05-06 2005-12-08 Molichem Medicines, Inc. Treatment of ocular diseases and disorders using lantibiotic compositions
EP1848541A4 (en) * 2005-02-07 2013-01-16 Pharmalight Inc METHOD AND DEVICE FOR OPHTHALMIC DELIVERY OF PHARMACEUTICALLY ACTIVE INGREDIENTS
US7368439B2 (en) * 2005-06-15 2008-05-06 Bar - Ilan University Dinucleoside poly(borano)phosphate derivatives and uses thereof
KR100870104B1 (ko) * 2005-11-28 2008-11-26 주식회사 머젠스 안구건조증 치료 및 예방용 조성물
JP5185139B2 (ja) * 2006-01-27 2013-04-17 キャン−ファイト・バイオファーマ・リミテッド ドライアイ疾患治療用アデノシンａ３レセプターアゴニスト
US20080107713A1 (en) * 2006-11-08 2008-05-08 Orilla Werhner C Contact lens as a sustained drug delivery implant
US20080317819A1 (en) * 2007-06-21 2008-12-25 Orilla Werhner C Iop lowering drug combination or non-combination loaded contact lens with zonal drug delivery areas
US20090004244A1 (en) * 2007-06-27 2009-01-01 Orilla Werhner C Iris design as a drug depot for zonal drug delivery by contact lens
US20090004245A1 (en) * 2007-06-28 2009-01-01 Orilla Werhner C Use of an iris simulated layer to allow aesthetic appearance drug loaded contact lens
JP2012515164A (ja) * 2009-01-09 2012-07-05 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 角膜障害を処置するための治療組成物
US9011861B2 (en) 2010-02-25 2015-04-21 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
US10413506B2 (en) 2010-04-03 2019-09-17 Praful Doshi Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia
EP3195858B1 (en) 2010-04-03 2019-08-07 Praful Doshi Medical devices including medicaments and methods of making and using same
EP2614838B1 (en) 2010-09-10 2016-04-20 Santen Pharmaceutical Co., Ltd. Diquafosol and hyaluronic acid or salts thereof for the treatment of dry eye
US9821159B2 (en) 2010-11-16 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Stimulation devices and methods
WO2012068247A1 (en) 2010-11-16 2012-05-24 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for treatment of dry eye
MY161032A (en) * 2010-12-28 2017-04-03 Santen Pharmaceutical Co Ltd Ophthalmic solution comprising diquafosol, method for producing the same, and method for inhibiting formation of insoluble precipitate
US11372340B2 (en) * 2011-04-06 2022-06-28 Kla Corporation Method and system for providing a quality metric for improved process control
KR20190002751A (ko) 2012-03-26 2019-01-08 산텐 세이야꾸 가부시키가이샤 디쿠아포솔 함유 점안액
EP2967817B1 (en) 2013-03-12 2021-03-10 Oculeve, Inc. Implant delivery devices and systems
JP6795975B2 (ja) 2013-04-19 2020-12-02 オキュリーブ， インコーポレイテッド 鼻刺激デバイス及び方法
ES2812752T3 (es) 2014-02-25 2021-03-18 Oculeve Inc Formulaciones de polímeros para estimulación nasolagrimal
JP6643313B2 (ja) 2014-07-25 2020-02-12 オキュリーブ， インコーポレイテッド ドライアイを治療するための刺激パターン
WO2016065213A1 (en) 2014-10-22 2016-04-28 Oculeve, Inc. Implantable nasal stimulator systems and methods
WO2016065211A1 (en) 2014-10-22 2016-04-28 Oculeve, Inc. Contact lens for increasing tear production
JP6735742B2 (ja) 2014-10-22 2020-08-05 オキュリーブ， インコーポレイテッド ドライアイの治療のための刺激装置及び方法
RU2742032C2 (ru) 2015-06-05 2021-02-01 Сантен Фармасьютикал Ко., Лтд. Терапевтическое средство против сухости глаз, характеризуемое нанесением на глаза пациентов с сухостью глаз, носящих гибкие контактные линзы
US10426958B2 (en) 2015-12-04 2019-10-01 Oculeve, Inc. Intranasal stimulation for enhanced release of ocular mucins and other tear proteins
US10252048B2 (en) 2016-02-19 2019-04-09 Oculeve, Inc. Nasal stimulation for rhinitis, nasal congestion, and ocular allergies
EP3452166A4 (en) 2016-05-02 2019-12-18 Oculeve, Inc. INTRANASAL STIMULATION FOR THE TREATMENT OF DISEASES OF MEIBOM'S GLANDS AND BLEPHARITIS
US10610095B2 (en) 2016-12-02 2020-04-07 Oculeve, Inc. Apparatus and method for dry eye forecast and treatment recommendation
KR20220163519A (ko) 2018-02-28 2022-12-09 산텐 세이야꾸 가부시키가이샤 디쿠아포솔 및 양이온성 폴리머를 함유하는 안과용 조성물
CN113518646B (zh) 2019-02-27 2023-12-12 参天制药株式会社 含有地夸磷索或其盐，乙烯基系高分子及纤维素系高分子的眼科用组合物
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
CN117771172A (zh) * 2019-08-27 2024-03-29 参天制药株式会社 含有地夸磷索或其盐、及聚乙烯吡咯烷酮的水性眼科用组合物
KR20210110055A (ko) * 2020-02-28 2021-09-07 주식회사 종근당바이오 P1, p4-디(우리딘 5'-)테트라포스페이트 나트륨염 4 수화물 결정형 a의 제조방법
KR102548710B1 (ko) 2020-12-24 2023-06-28 주식회사 종근당 디쿠아포솔 또는 이의 약제학적으로 허용가능한 염과 토코페롤을 함유하는 건성안 예방 또는 치료용 약제학적 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2330902A1 (de) * 1973-06-18 1975-03-20 Helmut Dr Med Zander Heilungsfoerderndes und vorbeugendes, zur aeusserlichen oertlichen anwendung auf der haut und im auge fuer mensch und tier bestimmtes arznei- bzw. hautpflegemittel
US4380239A (en) 1979-12-20 1983-04-19 The Hospital For Sick Children Intubation of lacrimal ducts
US4658816A (en) 1984-11-14 1987-04-21 Concept Incorporated Lighted canaliculus intubation sets
US4868154A (en) * 1986-02-19 1989-09-19 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with melanocyte stimulating hormones
US4753945A (en) * 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US4921485A (en) 1988-09-28 1990-05-01 Griffiths John D Catheter for use in the surgical correction of a nasolacrimal duct obstruction
US5062831A (en) 1988-09-28 1991-11-05 Griffiths John D Catheter for use in the surgical correction of a nasolacrimal duct obstruction
US5169386A (en) 1989-09-11 1992-12-08 Bruce B. Becker Method and catheter for dilatation of the lacrimal system
US5021043A (en) 1989-09-11 1991-06-04 C. R. Bard, Inc. Method and catheter for dilatation of the lacrimal system
US5292498A (en) * 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
US5345948A (en) 1993-04-08 1994-09-13 Donnell Jr Francis E O Method of performing translactrimal laser dacryocystorhinostomy
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
ATE335492T1 (de) * 1996-03-27 2006-09-15 Inspire Pharmaceuticals Inc Verfahren zur behandlung der ziliardyskinesie mit uridintriphosphaten und verwandten verbindungen
US5789391A (en) * 1996-07-03 1998-08-04 Inspire Pharmaceuticals, Inc. Method of treating sinusitis with uridine triphosphates and related compounds
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US6696425B2 (en) * 1997-02-06 2004-02-24 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
US6921755B2 (en) 1998-02-06 2005-07-26 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
TW567456B (en) * 2001-02-15 2003-12-21 Au Optronics Corp Apparatus capable of improving flicker of thin film transistor liquid crystal display
FR2904554B1 (fr) * 2006-08-04 2010-11-05 Zheng Xu Lipides moleculaires heterogenes cytotropes (lmhc), procede de preparation, et methodes de traitement de patients porteurs de cancers multiples

Also Published As

Publication number Publication date
AU6324198A (en) 1998-08-26
US6916794B2 (en) 2005-07-12
US7235535B2 (en) 2007-06-26
CA2280183A1 (en) 1998-08-13
NO329118B1 (no) 2010-08-30
NO993777D0 (no) 1999-08-04
MY120023A (en) 2005-08-30
JP3652707B2 (ja) 2005-05-25
JP2005015491A (ja) 2005-01-20
ES2325892T3 (es) 2009-09-23
ZA98979B (en) 1999-02-19
US6887858B1 (en) 2005-05-03
CA2280183C (en) 2008-04-22
KR20000070848A (ko) 2000-11-25
AU735684B2 (en) 2001-07-12
US7759322B2 (en) 2010-07-20
DK1003474T3 (da) 2009-07-20
US20050197316A1 (en) 2005-09-08
EP1003474A1 (en) 2000-05-31
ATE428400T1 (de) 2009-05-15
WO1998034593A1 (en) 1998-08-13
NZ337405A (en) 2001-07-27
BR9809562A (pt) 2001-10-02
JP2010111676A (ja) 2010-05-20
JP5373576B2 (ja) 2013-12-18
CN1151775C (zh) 2004-06-02
US20080009463A1 (en) 2008-01-10
DE69840746D1 (de) 2009-05-28
KR100378443B1 (ko) 2003-03-29
US20020103157A1 (en) 2002-08-01
JP4664027B2 (ja) 2011-04-06
CN1250369A (zh) 2000-04-12
US5900407A (en) 1999-05-04
JP2001504858A (ja) 2001-04-10
EP1003474B1 (en) 2009-04-15
US8097600B2 (en) 2012-01-17
US20100330164A1 (en) 2010-12-30
NO993777L (no) 1999-10-05
HK1025915A1 (en) 2000-12-01
PT1003474E (pt) 2009-06-26

Similar Documents

Publication Publication Date Title
ID23375A (id) Metode pengobatan penyakit mata kering dengan agonist-agonist reseptor purinergik
WO2000050024A3 (en) Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof
WO2001080844A3 (en) Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
CA2250188A1 (en) Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
AU2003287005B2 (en) Vaginal health products
US5972904A (en) Method of treating sinusitis with uridine triphosphates and related compounds
ATE276740T1 (de) Pharmazeutische zusammensetzung zur diagnose von lungenkrankheiten
ATE261982T1 (de) Salze von di(uridine 5'-tetraphosphate), verfahren zur herstellung und verwendungen davon
WO2007022541A3 (en) Method of treating dry eye disease with non-drying antihistamines
US6414033B1 (en) Drug dosage form based on the teorell-meyer gradient
US6696425B2 (en) Method of treating dry eye disease with purinergic receptor agonists
BR0110418A (pt) Método para tratamento da degeneração retiniana com agonistas do receptor purinérgico
US20190321292A1 (en) Ophthalmic formulation comprising citicoline carried by liposome for the treatment of glaucoma
US7056889B2 (en) Compounds that bind P2Y2 or P2Y1 receptors
US7256183B2 (en) Method for treating or preventing inflammatory diseases
IT1254280B (it) Composizioni farmaceutiche comprendenti monosialoganglioside gm1 o un suo derivato atte al trattamento della malattia di parkinson
JP2001302545A (ja) 清涼化剤
ATE260118T1 (de) Zusammensetzungen von adenosin a1 agonisten mit 5ht1 agonisten
PAVAN-LANGSTON Potential use of ocular-insert therapy in dry eyes